zurig价格

What's the price? Febuxostat (zurig) is a new type of selective non-purine xanthine oxidase (XO) inhibitor. The drug was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States in February 2009. In 2010, it was launched in France, the United Kingdom, Germany and other countries. It was approved to be put on the market in China in 2013. The domestic price of febuxostat is 10 yuan per tablet, 40mg/tablet. The recommended dosage of febuxostat is 40mg/day, which means that febuxostat costs about 300 yuan a month. Taking it for a long time can also put a lot of financial pressure on you.

At present, the Indian version of Febuxostat is on the market. Speaking of the Indian version of Febuxostat, many people may not know much about it. The Indian version of Febuxostat is produced by Zydus Pharmaceuticals Factory in India. The outer packaging is a blue carton, and the inside is a plastic bottle. The bottle is blue and white. Its official name should be zurig80. The specification is a bottle of 30 pills, each pill is 80 mg, and the main ingredient is Febuxostat. The Indian version of Febuxostat is 80mg*30 tablets/box, and its price is about $200.

India's zurig, as a substitute for febuxostat's original drug, has saved people a lot of money. I believe everyone knows that India is at the forefront of the world in the field of generic drugs. Therefore, the efficacy of the Indian version of febuxostat is guaranteed. Although Zurig in India is a generic drug, it is the same as the brand-name drug in terms of dosage, safety, efficacy, quality, effects, and indications.

Febuxostat is a gout drug that has become a "new favorite" in recent years. Febuxostat applied for marketing in Japan in early 2004. The FDA approved the marketing of febuxostat tablets in February 2009. The chemical name of febuxostat () is 2-[(3-cyano-4-isobutoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid. It is a xanthine oxidase (XO) inhibitor and is suitable for the long-term treatment of hyperuricemia with gout symptoms. It treats gout by reducing serum uric acid concentration by inhibiting uric acid synthesis. Febuxostat tablets are suitable for long-term treatment of hyperuricemia in patients with gout, but are not recommended for use in asymptomatic hyperuricemia.